Allos Therapeutics Inc. (ALTH)

[surf1944]

3:09AM Allos Therapeutics: COMPLETE registry provides first glance into treatment patterns for patients with peripheral T-Cell lymphoma (ALTH) 1.85 : Co presents initial data from COMPLETE, an international registry designed to address the urgent need for an increased understanding of the treatment patterns and outcomes for patients with peripheral T-cell lymphoma. Baseline characteristics presented show the average patient age to be 58 years with slightly more men enrolled in the registry to date (44 men (59%) and 30 female (41%); the most common PTCL subtypes are PTCL-NOS (18 of 74 patients; 24%), ALCL (13 of 74 patients; 18%), AITL (11 of 74 patients; 15%), T/NK cell lymphoma, nasal type (7 of 74 patients; 10%), and transformed mycosis fungoides (7 of 74 patients; 10%). Treatment records show the most common initial treatment to be induction chemotherapy alone (17 of 26 patients; 65%).